The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats

The Lancet Infectious Diseases

Volumn 16, Issue 1, 2016, Pages e1-e9

  Osterholm, Michael ^a   Moore, Kristine ^a   Ostrowsky, Julie ^a   Kimball Baker, Kathleen ^a   Farrar, Jeremy ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE; MENINGOCOCCUS VACCINE;

AFRICA; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; FUNDING; HUMAN; INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC HEALTH PROBLEM; RAPID RESPONSE TEAM; REVIEW; THREAT; VACCINATION; VIRAL CLEARANCE; ADVISORY COMMITTEE; COMMUNICABLE DISEASES, EMERGING; HEALTH; HEALTH CARE POLICY; HEALTH SERVICE; HEMORRHAGIC FEVER, EBOLA; PREVENTIVE HEALTH SERVICE; PUBLIC-PRIVATE PARTNERSHIP; TRENDS;

ADVISORY COMMITTEES; COMMUNICABLE DISEASES, EMERGING; EBOLA VACCINES; GLOBAL HEALTH; HEALTH POLICY; HEALTH SERVICES NEEDS AND DEMAND; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNIZATION PROGRAMS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; VACCINATION;

EID: 85027933878     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00416-8     Document Type: Review

References (71)

1. WHO. International Health Regulations (2005). Second Edition. http://apps.who.int/iris/bitstream/10665/43883/1/9789241580410_eng.pdf (accessed Oct 27, 2015).
2. WHO. Ebola Response Roadmap. http://apps.who.int/iris/bitstream/10665/131596/1/EbolaResponseRoadmap.pdf?ua=1, Aug 28, 2014 (accessed Oct 27, 2015).
3. WHO. Experimental Ebola vaccines. http://who.int/mediacentre/news/ebola/01-october-2014/en/, Oct 1, 2014 (accessed Sept 2, 2015).
4. Kanapathipillai, R, Ebola Vaccine — An Urgent International Priority. N Engl J Med 371 (2014), 2249–2251.
5. Wellcome Trust/CIDRAP. Recommendations for accelerating the development of Ebola vaccines. http://www.cidrap.umn.edu/sites/default/files/public/downloads/ebola_virus_team_b_report-final-021615.pdf (accessed Sept 2, 2015).
6. Ye, L, Yang, C, Development of vaccines for prevention of Ebola virus infection. Microbes Infect 17 (2015), 98–108.
7. Falzarano, D, Geisbert, TW, Feldmann, H, Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines 10 (2011), 63–77.
8. Geisbert, TW, Bausch, DG, Feldmann, H, Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 20 (2010), 344–357.
9. Tully, CM, Lambe, T, Gilbert, SC, Hill, AVS, Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. Lancet Infect Dis 15 (2015), 356–359.
10. WHO. WHO high-level meeting on Ebola vaccines access and financing. http://www.who.int/mediacentre/news/ebola/23-october-2014/en/, Oct 23, 2014 (accessed Oct 27, 2015).
11. WHO. A system for the prequalification of vaccines for UN supply. http://www.who.int/immunization_standards/vaccine_quality/pq_system/en/, 2014 (accessed Sept 2, 2015).
12. Boateng, EK, Overview of regulatory perspective from AVAREF representative. http://www.who.int/immunization/diseases/ebola/10-AVAREF_Talk.pdf (accessed Oct 27, 2015).
13. Krause, PR, Cavaleri, M, Coleman, G, Gruber, MF, Approaches to demonstration of Ebola virus vaccine efficacy. Lancet Infect Dis 15 (2015), 627–629.
14. US, FDA. Assessing the safety of vaccines at the FDA: pre- and post-licensure evaluation. Office of Vaccines Research and Review Center for Biologics Evaluation and Research, US Food and Drug Administration. http://www.who.int/immunization/diseases/ebola/Finn_WHO_Sept_29_2014.pdf (accessed Sept 2, 2015).
15. WHO. 9th Annual Meeting of the African Vaccine Regulatory Forum (AVAREF). Pretoria, Nov 3–7, 2014. Recommendations. http://www.who.int/immunization_standards/vaccine_regulation/avaref_meeting_recommendations_14nov2014.pdf?ua=1 (accessed Oct 27, 2015).
16. US Food and Drug Administration. FDA briefing document. Vaccines and Related Biological Products Advisory Committee Meeting Licensure of Ebola Vaccines: demonstration of effectiveness. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM461916.pdf, Sept 15, 2015 (accessed Oct 27, 2015).
17. D'Agostino, RB, Massaro, JM, Sullivan, LM, Non-inferiority trials: design concepts and issues—the encounters of academic consultants in statistics. Stat Med 22 (2003), 169–186.
18. Rid, A, Saxena, A, Baqui, AH, et al. Placebo use in vaccine trials: Recommendations of a WHO expert panel. Vaccine 32 (2014), 4708–4712.
19. Greenwood, B, The use of a placebo in vaccine trials. Lancet 383 (2014), 2101–2102.
20. Ouandaogo, CR, Yaméogo, TM, Diomandé, FVK, et al. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. Vaccine 30 (2012), B46–B51.
21. Black, S, Eskola, J, Siegrist, CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 374 (2009), 2115–2122.
22. Orenstein, LAV, Orenstein, EW, Teguete, I, et al. Background rates of adverse pregnancy outcomes for assessing the safety of maternal vaccine trials in sub-Saharan Africa. PLoS One, 7, 2012, e46638.
23. Kruger, M, Ndebele, P, Horn, L, (eds.) Research ethics in Africa: a resource for ethics committees, 2014, Sun Press, Stellenbosch.
24. Rid, A, Emanuel, EJ, Ethical considerations of experimental interventions in the Ebola outbreak. Lancet 384 (2014), 1896–1899.
25. Ali, M, Sur, D, You, YA, et al. Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India. Clin Infect Dis 56 (2013), 1123–1131.
26. Chao, DL, Halloran, ME, Longini, IM, Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. Proc Natl Acad Sci USA 108 (2011), 7081–7085.
27. Fenner, F, Smallpox and its eradication. J Epidemiol Community Health, 43, 1989, 92.
28. Levine, H, Rishpon, S, Huerta-Hartal, M, Davidovitch, N, Preventing mumps outbreaks in confined settings: comprehensive ring vaccination as a containment strategy. Hum Vaccin 7 (2011), 1389–1393.
29. Luquero, FJ, Grout, L, Ciglenecki, I, et al. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med 370 (2014), 2111–2120.
30. Poland, GA, Grabenstein, JD, Neff, JM, The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 23 (2005), 2078–2081.
31. Vawter, DE, Gervais, KG, Garrett, JE, Allocating pandemic influenza vaccines in Minnesota: recommendations of the Pandemic Influenza Ethics Work Group. Vaccine 25 (2007), 6522–6536.
32. Djingarey, MH, Barry, R, Bonkoungou, M, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 30 (2012), 40–45.
33. WHO Ebola Response Team. Ebola virus disease in west Africa—the first 9 months of the epidemic and forward projections. N Engl J Med 371 (2014), 1481–1495.
34. Dhillon, RS, Kelly, JD, Community trust and the Ebola endgame. N Engl J Med 373 (2015), 787–789.
35. Elemuwa, C, Kutalek, R, Ali, M, et al. Global lessons from Nigeria's ebolavirus control strategy. Expert Rev Vaccines 14 (2015), 1397–1400.
36. Nasir, S-G, Aliyu, G, Ya'u, I, et al. From intense rejection to advocacy: how Muslim cerics were engaged in a polio eradication initiative in northern Nigeria. PLoS Med, 11, 2014, e1001687.
37. Nwaze, E, Mohammed, AJ, An impact evaluation of the engagement of traditional and religious leaders in the Nigerian polio eradication initiative. Sch J Med 3 (2013), 53–63.
38. The Lancet Infectious Diseases. Global harmonisation in vaccine price. Lancet Infect Dis, 15, 2015, 249.
39. Wellcome Trust/CIDRAP. Ebola Vaccine Clinical Trials–Team B Situation Update. http://www.cidrap.umn.edu/sites/default/files/public/downloads/ebola_vaccine_clinical_trials_team_b_situation_update_aug_2015.pdf, 2015 (accessed Sept 2, 2015).
40. Agnandji, ST, Huttner, A, Zinser, ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe—preliminary report. N Engl J Med, 2015, 10.1056/NEJMoa1502924 published online April 1.
41. Henao-Restrepo, AM, Longini, IM, Egger, M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386 (2015), 857–866.
42. Huttner, A, Dayer, J-A, Yerly, S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 15 (2015), 1156–1166.
43. Ledgerwood, JE, DeZure, AD, Stanley, DA, et al. Chimpanzee adenovirus vector Ebola vaccine—preliminary report. N Engl J Med, 2014, 10.1056/NEJMoa1410863 published online Nov 26.
44. Rampling, T, Ewer, K, Bowyer, G, et al. A monovalent chimpanzee adenovirus Ebola vaccine—preliminary report. N Engl J Med, 2015, 10.1056/NEJMoa1411627 published online Jan 28.
45. Regules, JA, Beigel, JH, Paolino, KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine—preliminary report. N Engl J Med, 2015, 10.1056/NEJMoa1414216 published online April 1.
46. Zhu, F, Hou, L, Li, J, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 385 (2015), 2272–2279.
47. WHO. Ebola vaccines, therapies, and diagnostics. http://www.who.int/medicines/emp_ebola_q_as/en/, 2015 (accessed Sept 2, 2015).
48. Halloran, ME, Longini, IM, Struchiner, CJ, Design and interpretation of vaccine field studies. Epidemiol Rev 21 (1999), 73–88.
49. Ebola ça suffit ring vaccination trial Consortium. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference. BMJ, 351, 2015, h3740.
50. Halloran, ME, Struchiner, CJ, Longini, IM Jr, Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 146 (1997), 789–803.
51. WHO. Ebola vaccine phase III clinical trial, Guinea. Next steps. http://www.who.int/medicines/ebola-treatment/vax_phase3_next-steps/en/, 2015 (accessed Sept 6, 2015).
52. WHO. Guinea Ring Vaccination trial extended to Sierra Leone to vaccinate contacts of new Ebola case. http://www.afro.who.int/en/sierra-leone/press-materials/item/7962-guinea-ring-vaccination-trial-extended-to-sierra-leone-to-vaccinate-contacts-of-new-ebola-case.html, 2015 (accessed Sept 6, 2015).
53. Cooper, CL, Bavari, S, A race for an Ebola vaccine: promises and obstacles. Trends Microbiol 23 (2015), 65–66.
54. WHO. Draft framework for formulating recommendations for the deployment of Ebola vaccines. http://www.who.int/immunization/sage/meetings/2015/april/Rees_Ebola_Draft_framework_SAGE_Apr2015.pdf, 2015 (accessed Oct 27, 2015).
55. Callaway, E, Successful Ebola vaccine provides 100% protection in trial. Nature, 2015, 10.1038/nature.2015.18107 published online July 31.
56. Wilson, P, Giving developing countries the best shot: an overview of vaccine access and R&D. Oxfam International. https://www.msf.org.uk/sites/uk/files/Vaccine_Report_201005111518.pdf, 2010 (accessed Oct 27, 2015).
57. Hamidi, A, Boog, C, Jadhav, S, Kreeftenberg, H, Lessons learned during the development and transfer of technology related to a new Hib conjugate vaccine to emerging vaccine manufacturers. Vaccine 32 (2014), 4124–4130.
58. Milstien, JB, Gaulé, P, Kaddar, M, Access to vaccine technologies in developing countries: Brazil and India. Vaccine 25 (2007), 7610–7619.
59. WHO. Increasing access to vaccines through technology transfer and local production. http://www.who.int/phi/publications/Increasing_Access_to_Vaccines_Through_Technology_Transfer.pdf, 2011 (accessed Oct 27, 2015).
60. Heymann, DL, Rodier, GR, Ryan, MJ, Ebola vaccines: keep the clinical trial protocols on the shelf and ready to roll out. Lancet 385 (2015), 1913–1915.
61. WHO/UNICEF. Yellow fever initiative providing an opportunity of a lifetime. One injection, full protection. http://www.who.int/csr/disease/yellowfev/YFIbrochure.pdf, 2010 (accessed Oct 27, 2015).
62. WHO. Vaccines and vaccination against yellow fever. WHO position paper – June 2013. Wkly Epidemiol Rec 88 (2013), 269–284.
63. WHO. Oral cholera vaccine stockpile. http://www.who.int/cholera/vaccines/ocv_stockpile_2013/en/, 2013 (accessed Sept 2, 2015).
64. Norheim, G, Oftung, F, Watle, S, et al. Report to the Norwegian Ministry of Health. Vaccine-based mitigation of the 2014 Ebola Viral Disease (EVD) epidemic: gap analysis and proposal for Norwegian initiatives, 2014, Norwegian Institute of Public Health.
65. Gilchrist, SA, Nanni, A, Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance. Health Policy Plan 28 (2013), 838–846.
66. Plotkin, SA, Mahmoud, AAF, Farrar, J, Establishing a global vaccine-development fund. N Engl J Med 373 (2015), 297–300.
67. Berndt, ER, Hurvitz, JA, Vaccine advance-purchase agreements for low-income countries: practical issues. Health Aff 24 (2005), 653–665.
68. Mansoor, OD, Kristensen, D, Meek, A, et al. Vaccine presentation and packaging advisory group: a forum for reaching consensus on vaccine product attributes. Bull World Health Organ 91 (2013), 75–78.
69. The malERA Consultative Group on Vaccines. A research agenda for malaria eradication: vaccines. PLoS Med, 8, 2011, e1000398.
70. Lee, BY, Burke, DS, Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine 28 (2010), 2806–2809.
71. Lambert, WJ, Considerations in developing a target product profile for parenteral pharmaceutical products. AAPS PharmSciTech 11 (2010), 1476–1481.